ChemoCentryx to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
June 29 2016 - 8:30AM
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage
biopharmaceutical company developing orally-administered
therapeutics to treat autoimmune diseases, inflammatory disorders,
and cancer, today announced that Thomas J. Schall, Ph.D., President
and Chief Executive Officer, will present at the Cantor Fitzgerald
2nd Annual Healthcare Conference on Wednesday, July 13, 2016 at
9:30 a.m. ET. The conference will be held at the Le Parker Meridien
Hotel in New York, NY.
A live audio webcast of the presentation can be accessed through
the Investors section of the Company's website at
www.ChemoCentryx.com. A replay of the webcast will be available on
the Company's website for two weeks following the live
presentation.
About ChemoCentryx
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company
focused on discovering, developing and commercializing
orally-administered therapeutics that target the chemokine and
chemoattractant systems in order to treat autoimmune diseases,
inflammatory disorders and cancer. The chemokine system is a
biological network that regulates inflammation via a collection of
secreted chemokine molecules, or ligands, and their specific cell
surface receptors. Based on its proprietary drug discovery and drug
development platform, ChemoCentryx has generated multiple clinical
and preclinical-stage programs, each targeting distinct chemokine
and chemoattractant receptors with different small molecule
compounds. CCX168, a C5aR inhibitor, is in Phase II development for
the treatment of anti-neutrophil cytoplasmic
auto-antibody-associated vasculitis (AAV). CCX168 appears to be
safe, well tolerated and successful in allowing reduction and
elimination of high-dose steroids, part of standard of care for AAV
patients, without compromising efficacy or safety in clinical
studies to date. CCX168 is also in Phase II studies for the
treatment of atypical hemolytic uremic syndrome (aHUS) and
immunoglobulin A nephropathy, or IgA nephropathy (IgAN).
ChemoCentryx has licensed exclusive rights to Vifor Pharma to
commercialize CCX168 in Europe and certain other markets outside of
the U.S. and most of Asia. CCX872, a CCR2 inhibitor,
successfully completed Phase I development and is in development
for the treatment of non-resectable pancreatic cancer. CCX140, a
distinct CCR2 inhibitor, successfully completed a Phase II clinical
trial where it was shown to be safe and well tolerated while
demonstrating statistically significant improvement in albuminuria
in patients with diabetic nephropathy. Other clinical programs
include CCX507, a next generation CCR9 inhibitor, which has
successfully completed Phase I development, vercirnon (also known
as Traficet-EN or CCX282) a specific CCR9 inhibitor for the
treatment of inflammatory bowel disease, and CCX354, a CCR1
inhibitor which successfully completed a Phase II clinical trial
for the treatment of rheumatoid arthritis. ChemoCentryx also has
several programs in advanced preclinical development.
Source: ChemoCentryx, Inc.CCXI-G
Contacts:
Susan M. Kanaya
Senior Vice President, Finance and Chief Financial Officer
investor@chemocentryx.com
Media:
Denise Powell
denise@redhousecomms.com
510.703.9491
Investors:
Steve Klass
Burns McClellan
212.213.0006
sklass@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Sep 2023 to Sep 2024